About ABBV-744 as a potential therapeutic option for aggressive cancers
The present work examined the potential of using ARV-825 and ABBV-744 to improve the effectiveness of tamoxifen or fulvestrant plus palbociclib. ARV-825 was effective in equally p53 wild-type (WT) breast tumor cells and in cells missing functional p53 either alone or in combination with tamoxifen, while the effectiveness of ABBV-744 was limited to